MRC Centre for Inflammation Research
MRC Centre for Inflammation Research logo

Dr Alan Serrels

Alan Serrels' group study how cancer cells contribute to shaping the tumour immune environment, and develop/apply intravital imaging approaches for studying cancer-associated processes in vivo.

Dr Alan Serrels

Research Fellow

  • MRC Centre for Inflammation Research
  • Research Theme: Tissue Remodelling and Regeneration

Contact details

Group Members

  • Marta Canel - Postdoc (email)
  • Catherine Davidson - ECAT Fellow (email)
  • David Taggart - Postdoc (email)

Background

The focus of our lab is to understand how cancer cells contribute to regulating the composition of the tumour immune environment to promote evasion of the anti-tumour immune response. In this context, we recently identified a new role for the adhesion linked kinase Focal Adhesion Kinase (FAK) in regulating chemokine and cytokine expression in cancer cells, resulting in elevated levels of intra-tumoural Tregs and suppression of the CD8 T-cell anti-tumour immune response. Our current aim is to understand in greater detail the extent of FAKs immuno-modulatory activity, and to identify optimal combinations with current/emerging immunotherpies for translation to the clinic.

Research Overview

Reprogramming the tumour immune environment to promote an anti-tumour immune response has shown promise as a therapeutic approach in the fight against cancer. In preclinical murine models, targeting a variety of immune cell populations including macrophages and Tregs has shown anti-tumour efficacy either alone or when used in combination with agents that enhance CD8 T-cell activation. Our lab is interested in understanding how abberantly reglated signaling pathways in cancer cells contribute to orchestrating the immuno-suppressive tumour environment, and how targeting these can be used to potentiate anti-tumour immunity either alone or in combination with other immunotherapies. In this context we have identified a new role for Focal Adhesion Kinase (FAK), a non-receptor protein tyrosine kinase frequently upregulated in cancer. Best known for its functions downstream of integrins and growth factors receptors, FAK can also translocate to the nucleus where its function remains poorly characterised. We have recently identified that nuclear FAK can regulate the transcription of chemokines and cytokines important in controling the anti-tumour immune response (Serrels et al, Cell, 163, Sept 2015). Furthermore, comparison of nuclear FAK levels between Squamous Cell Carcinoma (SCC) cells and skin keratinocytes (the normal cell counterpart to the SCCs) has shown elevated levels of nuclear FAK in cancer cells, implying that oncogenic transformation may trigger its nuclear accumulation. Thus, FAK represents a new target for immunotherapy, and modulating its nuclear function may yield cancer specific responses. Understanding the extent and mechanistic basis of FAK-dependent immune modulation in cancer and identifying optimal combinations with other immunotherapies are key aims of the lab. To address our research questions, we use a combination of cutting edge genome editing, gene expression analysis, proteomics, flow cytometry, and advanced intra-vital imaging.

Sources of Funding

Information on funding at Alan Serrels' Research Explorer profile.